<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920348</url>
  </required_header>
  <id_info>
    <org_study_id>IRO-93326</org_study_id>
    <nct_id>NCT00920348</nct_id>
  </id_info>
  <brief_title>The Canadian Cohort Obstructive Lung Disease</brief_title>
  <acronym>CanCOLD</acronym>
  <official_title>The Canadian Cohort Obstructive Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Almirall, SAS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abstract Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in
      Canada. COPD is not just a disease of men, nor is it solely a disease in old age. Women have
      been underrepresented and early disease has not been studied. Underdiagnosis of COPD remains
      a significant problem, and it may indicate an unmet healthcare need. This can potentially
      results not only in a patient been misinformed, but can lead to incorrect management.

      Epidemiological research is needed to develop a framework to combat this major health
      problem, by better characterization of the population of men and women at risk and patients
      with early disease, by better understanding which factors modifiable through health
      interventions are related to health perception (health-related quality of life) and disease
      evolution.

      This will be possible through a nationwide study, the Canadian Cohort Obstructive Lung
      disease (CanCOLD), a prospective longitudinal study. The CanCOLD study is built on the
      current ongoing prevalence nationwide study, the Canadian Obstructive Lung disease &quot;COLD&quot;
      study.

      The CanCOLD will be the first study to assess prevalence of disease across Canada and its
      consequence in men and women, and to evaluate a conceptual model of disease severity based on
      patient's health perception (health-related quality of life). Ultimately, this project will
      extend to a longitudinal follow up (3 years or beyond) and will allow to have a better
      understanding of the lifestyle risk factors, not only smoking but also diet, physical
      activity, and co morbid conditions. This will be a great asset to shift from management of a
      single risk factor (tobacco control) to total COPD risk management. The results of the study
      will greatly help to assist decision makers in developing policies to improve the diagnosis,
      the management of COPD and to optimize health care services use.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>What risk factors other than smoking determine the development and progression of COPD.</measure>
    <time_frame>One visit a year every 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>What are the combinations of the disease and patient attributes that differentiate individuals (men/women) with COPD as they relate to relevant outcomes (symptoms, exacerbations, disease progression or death)</measure>
    <time_frame>One visit a year 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Is early detection of COPD with spirometry meaningful according to sex and ageing.</measure>
    <time_frame>One visit a year 18 months</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>COPD</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC&lt;0.70 and FEV1&lt;80% of pred.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>COPD mild (GOLD1)(post-BD FEV1/FVC&lt;0.70 AND FEV1&gt;=80% of pred.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>COPD at risk (ever smoker with post-BD FEV1/FVC&gt;=0.70)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>&quot;Healthy control&quot; never smokers without respiratory disease (post-BD FEV1/FVC&gt;=0.70.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling

        -  Biomarkers:IL-6, CRP, CC-16, SP-D&quot;

        -  DNA for genetics, epigenetic and RNA for transcriptomics

        -  Markers for cardiovascular diseases: LDL, LDL and HDL sizes, Apo B, Apo A1, CRP, IL6,
           TNF alpha, Adiponectine, Leptine, Glucose and Insulin.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects' selection and participation in CanCOLD- longitudinal cohort: Subjects will be
        recruited from the study site participants (total from cross-sectional ≈5,000 subjects, men
        and women).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All the subjects have taken part in the COLD study, a true population based prevalence
             study. Subjects must have an inclusion criteria of 40 years and older to participate
             in the COLD study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Bourbeau, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wan Tan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAAA University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Maltais, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CFBA Université Laval</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shawn Aaron, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHGC Ottawa Hospital General Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis O'Donnell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDA Queen's University (Kinsgston)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darcy D Marciniuk, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCAA University of Saskatchewan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Cowie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CBBA University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth R. Chapman, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEAA University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Hernandez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHAA Dalhousie University (Nova Scotia)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark J. FitzGerald, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAAA University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald Sin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAAA University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Benedetti, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>INUD McGill University Healty Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Lacasse, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CPVR Institut universitaire de cardiologie et de pneumologie de Québec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Ernst, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harvey Coxson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Goldstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEAA University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlo Marra, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAAA University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halifax Infirmary</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital General</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Jean Bourbeau</investigator_full_name>
    <investigator_title>MD, M.Sc.</investigator_title>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Cohort study</keyword>
  <keyword>prospective longitudinal study</keyword>
  <keyword>tissue bank</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>publications; data sharing through substudies submission</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

